Many studies have shown that sialyl Lewis X (sLe X ) is related to cancer prognosis and clinicopathology, but failed to provide conclusive results. We conducted the present meta-analysis to identify the association between sLe X overexpression and cancer prognosis.
Introduction
As is known to all, cancer is a common life-threatening disease. According to recent studies, the incidence of cancer increases 1% per year in Europe. 1 Among the adult population, a rising trend is reported for soft tissue sarcoma. 2 Breast, colorectal, prostate, and lung cancers are the most common oncological cause for death among the European population. 3 Cancer cannot be cured, as expected, due to the limited knowledge of iatrotechnique. So, exploration of more precise bio-indicators is valuable for early diagnosis of cancer and improving prognosis of patients.
Cell surface carbohydrates are involved in various biological processes such as cellular differentiation, maturation, proliferation, and malignant transformation. 4 Dramatic changes of cell surface carbohydrates are associated with cancer occurrence, tumor invasiveness, and metastatic behavior. 5 Sialyl Lewis X (sLe X ) (NeuNAcα2,3Galβ1,4[Fucα1,3] GlcNAc), a carbohydrate antigen, is related to cell adhesion and our previous study showed that inhibition of sLe X synthesis leads to decreased adhesion of trophoblast cells to endometrial epithelial cells. 6 Also, sLe X is frequently expressed in human cancer cells and primary tumors. 7, 8 As a ligand for E-selectin and L-selectin, sLe X is related to cell adhesion. 9 It has been demonstrated that sLe X was involved in the adhesion of tumor cells to vascular endothelium. 10 The potential role of sLe X in the tumor metastatic process has been supported by several clinical studies. [11] [12] [13] [14] Many studies have identified the relationship between sLe X and cancer prognosis, but individual studies of the influence of sLe X expression in cancer have failed to 
Materials and methods

Publication search
We searched published studies in the PubMed and Embase databases up to May 2014 with the following search terms: (slex OR sialyl lewis x) AND (cancer OR neoplasms OR carcinoma OR tumor) AND prognosis. Furthermore, reference lists of main reports and review articles were also reviewed to identify additional relevant publications. The study was conducted and reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
selection criteria
Two authors (YL and JXL) reviewed the retrieved titles and abstracts to discriminate the eligible studies for inclusion in our meta-analysis independently. Published studies were included based on the following criteria: 1) written and published in English; 2) patients with cancer diagnosis by pathology; 3) studies about sLe X expression in cancer tissues; 4) sLe X expression was measured by immunohistochemistry (IHC) method; 5) full length paper with sufficient data on sLe X expression and prognosis and prognosis-related factors; 6) we could find the full text. We excluded studies with the following criteria: 1) written and published in a language other than English; 2) studies about cell lines and animals; 3) studies about sLe X expression in serum; 4) review articles without original data; 5) a commentary, letter to the editor, or monograph.
Data extraction
Two authors (YL and WG) performed the data evaluation independently. The following data were extracted from each study: the first author's last name; publication year; country; cancer source; number of patients; number of sLe X expressions (positive/negative); clinicopathological factors (age, sex, tumor size, histological differentiation, lymphatic invasion, venous invasion, T/N/M stage, tumor stage, and recurrence); survival analysis.
Data synthesis and statistical analysis
Expression of sLe X was analyzed as dichotomous variables, as positive expression versus negative expression. The clinicopathological factors were also conducted as dichotomous variables, as older age versus younger age for age; male versus female for sex; large versus small for tumor size; high versus low for histological differentiation; I and II versus III and IV for tumor stage; pT2 versus more than pT3 for depth of invasion (T stage); with versus without for lymphatic invasion, venous invasion, lymph node metastasis (N stage), distant metastasis (M stage), recurrence. Survival of sLe X expression was analyzed by Cox's regression analysis conducted as hazard ratio (HR) and 95% confidence interval (95% CI). The data of expression of sLe X and clinicopathological factors or survival rate were extracted and calculated by initial data of studies. These data were analyzed with random-effect method, and were measured in relative risk (RR) with 95% CI. Statistical heterogeneity was estimated by means of Cochran's Q test and I 2 test. The I 2 test represents the percentage of variation to heterogeneity, which is categorized as low (0%-40%), moderate (40%-60%), high (60%-90%), very high (.90%). Subgroup analyses were carried out based on cancer or country of the included studies if a significant heterogeneity was found in overall meta-analysis. To identify any potential publication bias, we used Begg's test. All statistical analyses were performed with Review Manager 5.2 and STATA 12.0.
Results
systematic review
We identified 178 studies that fit our search strategy, 41 studies were identified in our primary search (Figure 1) . Finally, 29 studies published between 1993 and 2013 were included in our meta-analysis. 11, 12, Detailed characteristics of these studies are provided in Table 1 Meantime, we found that sLe X overexpression was not significantly related to cancer prognosis and clinicopathology factors, including age (older versus younger) (pooled RR =1.08, 95% CI: 0.97-1.21, I 2 =0.0%), sex (male versus female) (pooled RR =0.97, 95% CI: 0.88-1.07, I 2 =47.0%), tumor size (larger versus smaller) (pooled RR =1.23, 95% CI: 0.94-1.62, I 2 =51.1%), tumor differentiation (lower differentiation versus higher differentiation) (pooled RR =0.94, 95% CI: 0.72-1.21, I 2 =75.1%) ( Figure 2B ).
sle X overexpression on cancer survival
Eight studies analyzed the overall survival (OS) of human cancer with positive/negative sLe X overexpression, the HRs ranged from 2.42 to 9.10. 18, 30, 32, [34] [35] [36] 38, 39 The summarized HR of negative versus positive was 3.11 (95% CI: 2.25-4.32) with low heterogeneity (I 2 =0.0%) ( Figure 3 ).
subgroup analyses
We chose subgroup analyses in meta-analysis with relative high heterogeneity (I 2 .40%). In subgroup analyses, studies were stratified by cancer category (colorectal cancer, gastric cancer, lung cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, oral squamous cell carcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, prostate cancer, and extrahepatic bile duct carcinoma) or ethnicity (Asia, America, and Europe). In addition, most of these analyses showed low heterogeneity after stratification (Tables 2 and 3) .
Publication bias
Begg's test was created for assessment of possible publication bias. It suggested that publication bias had little influence on these meta-analysis results (P.0.05) (Figure 4 ).
Discussion
The cancer statistics of the USA, in 2013, 41 clearly indicated that the methods of treatment for cancer need to be improved. Exploring new molecular biological prognostic and predictive markers is a hot topic in modern medicine. Nakagoe et al first reported that sLe X was expressed in serum of patients with gastric and colorectal cancer as a tumorassociated carbohydrate antigen, which was also proven by clinicopathological and immunohistochemical studies. 42 The relationship between sLe X expression and cancer prognosis was identified by a number of studies, which did not show conformable results. To our knowledge, this is the first meta-analysis that systematically evaluates the relationship between sLe X expression and cancer prognosis and clinicopathology.
In the present study, a combined analysis of 29 articles (3,253 cancer patients) which showed the detection of high sLe X expression in tumor tissues with poor prognosis outcome in cancer patients was conducted. Our results indicated that sLe X expression was significantly correlated with lymphatic invasion, venous invasion, deep invasion (T stage), lymph node metastasis (N stage), distant metastasis (M stage), tumor stage, tumor recurrence, and OS. On the other hand, although a high level of sLe X expression was found in patients like the elderly, females, or patients with large size tumor and high differentiation, these results did not show any significance.
What makes sLe X overexpression account for the poor prognosis in cancer? By chemical analyses, it was shown that sLe X oligosaccharide was the minimal structure binding to E-, L-, and P-selectin, 43 which was closely involved in the interaction between the endothelium and cancer cells. sLe X is most commonly found in malignant tumors and plays a key role in cancer stem cell metastasis, hypoxia, and TNF-α, and promotes tumor adhesion, invasion, and metastasis by upregulating the sLe X expression in the tumor microenvironment. [44] [45] [46] In the present meta-analysis study, we also found that sLe X expression was correlated with tumor recurrence. On the other hand, it is widely accepted that expression of cell surface carbohydrates is altered during malignant transformation and tumor progression, and may influence determination of metastatic behavior of tumor cells. 21, 47 It has been identified that sLe X was a terminal tetrasaccharide moiety present on numerous membrane glycoproteins and glycolipids of epithelial and lymphatic cells. 28 With such characters, a high level of sLe X contributes to cell adhesion, metastasis, and invasion because the cell surface antigens can combine with other cells directly. sLe X in conjunction with mucins, promotes cellular motility, thus contributing to tumor cell spreading and metastasis. 11, 48 Furthermore, sLe X is expressed on granulocytes and monocytes which mediates inflammatory extravasation. 49, 50 However, the molecular biological mechanisms of how sLe X overexpression affects the cancer prognosis are complicated and still need further exploration. For the first time, our meta-analysis study revealed that sLe X could be a potential biomarker for poor cancer prognosis. Due to the differences in nationality and cancer types which could cause heterogeneity among the studies, we conducted a subgroup analysis. In the subgroup analysis, the sLe X overexpression may play different roles caused by differentiation, venous invasion, T stage, M stage, tumor stage, and sex factors among different types of cancers. These factors contribute to the possible presence of heterogeneity between the studies. The difference might be owing to the molecular biological mechanisms of interactions between sLe X overexpression, and the occurrence and development of different types of cancers. Otherwise, ethnicity may be another factor that contributes to heterogeneity in sex, tumor size, differentiation, venous invasion, T stage, and M stage. It might be owing to the differences in genetic backgrounds and the environment among different races. We also found high heterogeneity in some subgroups, because biological behavior of cancer might be affected by many possible factors during the complicated process of tumor development.
Some limitations of this meta-analysis need to be acknowledged. First, all published studies and papers were written in English, some related published or unpublished studies that met the inclusion criteria were missed. Most of the studies reported positive results, while studies of negative results were all rejected. Second, some cancers such as oral squamous cell carcinoma, gallbladder cancer, pancreatic ductal adenocarcinoma, prostate cancer, and extrahepatic bile duct carcinoma were included in only one article respectively, so we could not evaluate pooled data in subgroup analyses. Third, all of the included studies had data of the sLe X expression which was detected by IHC methods. It might have some bias because of different antibodies and different standards of positive/negative sLe X expression. However, it was not available for us to do a subgroup analysis to analyze the underlying bias of IHC on the pooled odds ratios or HRs. Finally, multivariate analyses were not performed on OS data in most included studies, we calculated the pooled HR only from available HRs.
In conclusion, our meta-analysis showed that a high level of sLe X expression was significantly associated with lymphatic invasion, venous invasion, deep invasion, lymph node metastasis, distant metastasis, tumor stage, tumor recurrence, and OS in cancer. sLe X might be a new prognostic biomarker, and it might become a new diagnostic and therapeutic target for cancer. Further studies are required to explore the molecular biological mechanisms of sLe X and factors that caused significant heterogeneity in the present meta-analysis study.
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